Abstract
Tamoxifen decreases serum cholesterol (S-cholesterol) level about 10% and low-density lipoprotein cholesterol (S-LDL) 15–20%, but in most studies it has increased serum triglyceride levels and had little effect on serum high-density cholesterol (S-HDL). The effect of another antiestrogen, toremifene, on the serum lipid profile has not been completely studied. We monitored serum lipid levels longitudinally in 141 axillary node-positive postmenopausal breast cancer patients who received randomly either 40 mg toremifene or 20 mg tamoxifen as adjuvant therapy for 36 months, and in 34 postmenopausal women who received no adjuvant systemic therapy after surgery for axillary node-negative breast cancer. No significant differences were found between the drugs in their effects on S-cholesterol, LDL, HDL, or triglyceride levels, or on the cholesterol-to-HDL or LDL-to-HDL ratios. For both drugs the S-cholesterol and S-LDL absolute lowering effect was the greater the higher the pretreatment level. For a patient with a median pretreatment value, toremifene decreased S-cholesterol 6% and tamoxifen 13%, and S-LDL decreased by 13% and 23%, respectively, at 6 months of therapy. Six months after stopping three-year antiestrogen therapy S- cholesterol and S-LDL levels had returned to the pretreatment levels. In conclusion, we found no major differences between 40 mg toremifene and 20 mg of tamoxifen in their effect on the serum lipid levels, which return to the pretreatment levels within 6 months after cessation of therapy.
Similar content being viewed by others
References
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467, 1998
Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609–1618, 1998
McDonald CC, Steward HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. The Scottish Breast Cancer Committee. Br Med J 303: 435–437, 1991
Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85: 1398–1406, 1993
Fisher B, Costantino JP, Wickerham L, Redmont CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371–1388, 1998
Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89: 776–782, 1997
Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82: 1327–1332, 1990
Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with nodepositive breast cancer. J Clin Oncol 14: 429–433, 1996
Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U: Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90: 1461–1467, 1998
Grey AB, Stapleton JP, Evans MC, Reid IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80: 3191–3195, 1995
Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659–663, 1994
Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, Singh R: The effect of tamoxifen and hormone replacement therapy on S-cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7: 671–675, 1996
Ballantyne CM: Current thinking in lipid lowering. Am J Med 104: 33S–41S, 1998
Miller M: Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J Suppl H: H18–22, 1998
Hayes DF, Van Zyl JA, Hacking A, Goelhals L, Bezwoda WR, Maillard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566, 1995
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972
Scandinavian Simvastatin Survival Study group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389, 1994
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307, 1995
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Brunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001–1009, 1996
The long-term intervention with pravastatin in ischaemic disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357, 1998
Hozumi Y, Kawano M, Miyata M: Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 44: 745–749, 1997
Pedersen TR, Olsson AG, Faegeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453–1460, 1998
Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 339: 12–20, 1998
Sacks FM, Walsh BW: Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 5: 236–240, 1994
Darling GM, Johns JA, McCloud PI, Davis SR: Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl JMed 337: 595–601, 1997
Grainger DJ, Witchell CM, Metcalfe JC: Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1: 1067–1073, 1995
Rights and permissions
About this article
Cite this article
Joensuu, H., Holli, K., Oksanen, H. et al. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63, 225–234 (2000). https://doi.org/10.1023/A:1006465732143
Issue Date:
DOI: https://doi.org/10.1023/A:1006465732143